Reply  by Mullens, Wilfried et al.
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tasodilator Therapy
n Cardiac Failure
hat Was New Is Old
he paper by Mullens et al. (1) and editorial comment by Yancy
2) draw attention to use of vasodilators in treatment of acute and
hronic refractory cardiac failure. The importance of left ventric-
lar (LV) afterload is stressed, but this is described only in terms
f peripheral resistance as the ratio of mean arterial pressure and
ardiac output, with the latter requiring and justifying right heart
atheterization. There is a problem with this approach over and
bove the risks of Swan-Ganz catheter use; peripheral resistance is
nly part of LV afterload, which is best expressed as aortic input
mpedance (3,4). In addition to peripheral resistance, impedance
lso considers aortic stiffness and wave reflection, and the effects of
asodilator drugs on these (3–5). In the recent articles, brachial
ystolic pressure is taken as an index of LV afterload, but this is
onsiderably higher than aortic and LV systolic pressure, especially
n patients with cardiac failure and during use of vasodilators
4–6). Vascular impedance in cardiac failure during use of vaso-
ilator drugs is not mentioned in either article, but has been
escribed in major journals over the past 3 decades, and forms the
asis for modern treatment of this condition (3,4). Central aortic
ressure also can be estimated accurately through noninvasive
ethods (4,6), as can indices of arterial stiffness and wave
eflection (4,5).
Persons wishing to apply the principles described by Mullens
t al. (1) and Yancy (2) are advised to consider these issues. They
an measure LV afterload better, and avoid invasive catheterization
ompletely. They can also obtain a more accurate measure of mean
rterial pressure from integration of the arterial pressure waveform
sing applanation tonometry, rather than estimating this from the
naccurate formula of diastolic  one-third pulse pressure (4).
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eply
e thank Drs. O’Rourke and Nichols for their enthusiastic
nterest and insightful comments regarding our report on the
otential benefits of sodium nitroprusside (SNP) in the setting of
dvanced decompensated heart failure (ADHF) (1). We are in
omplete agreement regarding the many factors that influence left
entricular (LV) afterload, including the concept that aortic
mpedance can be a more integrated measure of LV afterload. We
ould like to emphasize that throughout the article there had not
een any assertion or assumptions that measuring systemic vascular
esistance in ADHF better reflects LV afterload compared with
ortic input impedance. It is also not the intention of our
etrospective case series to compare the effectiveness or safety of
dministration of SNP guided by a reduction in vascular resistance
r aortic input impedance. In fact, titration of SNP doses was
ased on achieving a measured target mean arterial blood pressure
f 65 to 70 mmHg and not on achieving a normal derived systemic
ascular resistance. Nevertheless, even with this relatively crude
ethod in the absence of specialized equipment, the substantial
mprovement in cardiac output secondary to sodium nitroprusside
herapy was associated with more favorable (rather than adverse)
ong-term outcomes. Although invasive measurements were used
n our protocol, it is not the intention of these data to always imply
he need for invasive monitoring, but solely to understand the
emodynamic contributors and subsequent changes induced by
odium nitroprusside during the treatment of ADHF. As with
nterpreting the clinical utility of any biomarker, there is an
mportant distinction between identifying individual patients who
ay have the appropriate hemodynamic profiles to benefit from a
pecific intervention versus using specific indexes of LV afterload
s targets of therapeutic interventions. We agree that much
romise exists regarding the use of noninvasive hemodynamic
onitoring. Nevertheless, in much the same way that pharmaco-
herapeutics require rigorous placebo-controlled testing in the
pecific population with the specific treatment goals to be certain
f benefit, diagnostic tools intended to guide therapy may require
he same validation, especially regarding use in the acutely ill heart
ailure population.
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eply
he letter by Drs. O’Rourke and Nichols appropriately addresses
lternative modalities for assessing aortic impedance (a component
f left ventricular afterload), and importantly expands on our
arlier discussion regarding the measurement of peripheral resis-
ance and incorporating the use of those measurements in the
reatment of advanced decompensated heart failure. The paper by
ullens et al. (1) and accompanying editorial comment (2) do not
xclude other monitoring modalities, but rather address what is
ractically available and importantly highlight the potential benefit
f vasodilator therapy and emphasize the need to consider decom-
ensated heart failure as a disease entity driven not only by
ongestion but also by altered ventricular loading conditions.
here is reasonable hesitancy to the full embrace of the use of
itroprusside if indeed that use requires invasive hemodynamic
onitoring. Not only does invasive hemodynamic monitoring
eem to be necessary, but also skill in caring for such catheters in
n intensive care unit setting and skill in interpreting the data are
equired. Titrating the vasodilator dose to hemodynamics is yet
nother unique skill set required to use nitroprusside successfully in
his clinical scenario.
A noninvasive strategy that addresses one of several components
f left ventricular afterload, be it aortic impedance, brachial/radial
rterial resistance, or transthoracic bioimpedance, would be pref-
rable. The dilemma is that use of those noninvasive strategies in
n intensive care unit setting for patients with advanced decom-
ensated heart failure cannot be assumed to be accurate and
eproducible without undergoing prospective testing. The test
hould be proven to be reliable, reproducible, and accurate when
ompared with a known conventional hemodynamic parameter.
tility of certain modalities in the realm of hypertension is not
ufficient to verify utility in the setting of heart failure, especially
hen aortic flow characteristics and tissue factors related to
mpedance may be strikingly different. As well, if the noninvasive
trategy introduces a new metric, the ability to titrate therapy
ccording to that metric should be proven.
It is agreed that any evidence-based beneficial measurement of
eripheral resistance that obviates the need for right heart cathe-
erization would be preferable as greater use of vasodilator therapy
eems warranted in the setting of advanced decompensated heart
ailure.
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aloric Restriction Models
everse Metabolic Syndrome
he major metabolic effects of substantial weight loss in obese
atients with type 2 diabetes mellitus (1) provide a novel insight
nto the mechanisms postulated to underlie the metabolic syn-
rome. The diagnosis of metabolic syndrome requires the presence
f 3 of 5 characteristics: increased abdominal waist, hyperglycemia,
igh blood triglycerides, high blood pressure, and low high-density
ipoprotein (HDL) cholesterol. To tie these apparently disparate
anifestations together, an interesting hypothesis is that the
rucial initial event is the increased concentrations of circulating
ree fatty acids (FFAs) and cytokines derived from the excess
isceral abdominal fat (2). Although there are well-established
inks whereby increased circulating FFAs decrease the uptake of
lucose by heart (3) and skeletal muscle (4), it has been much more
ifficult to link chronically increased circulating FFAs to increased
lood triglycerides and decreased HDL cholesterol in humans.
The data of Hammer et al. (1) lead to the novel concept of the
reverse metabolic syndrome,” which can link excess circulating
FAs to the other metabolic changes in humans. Substantial
eight loss in obese patients with type 2 diabetes led to decreased
aist measurement (Fig. 1 of Hammer et al. [1]), decreased
irculating concentrations of glucose and triglycerides (and, hence,
y inference, increased HDL cholesterol), and decreased concen-
rations of the adverse cytokine, leptin. Another example of
eversed metabolic syndrome is the acute inhibition of lipolysis by
cipimox, which abruptly reduced circulating FFAs in obese
atients with type 2 diabetes, with rapid falls in plasma glucose and
nsulin, and decreases in muscle content of long-chain fatty acid (as
erivatives) (5). Furthermore, Hammer et al. (1) showed that as
lasma FFAs decrease, so do myocardial triglycerides. Conversely,
hronically increased circulating FFAs, when taken up by the
eart, form excess myocardial triglycerides (6), the basis of the
iastolic dysfunction that can extend to lipotoxic cardiomyopathy,
escribed in humans by Taegtmeyer’s group (6,7). These novel
oncepts add a potentially new dimension to the adverse effects of
xcessively high blood FFAs in metabolic syndrome.
Overall, the study by Hammer et al. (1) shows that unloading
he human body of adipose tissue induces a “reverse metabolic
yndrome.” This study provides additional data to support the
oncept that excess circulating FFA, as associated with abdominal
isceral obesity, is fundamental in the genesis of an increasingly
ommon human disease, namely, metabolic syndrome.
